Novel mRNA Signature for Anti-TNF-α Therapy Primary Response in Patients With Ulcerative Colitis.
Sign Up to like & getrecommendations! Published in 2023 at "Inflammatory bowel diseases"
DOI: 10.1093/ibd/izad060
Abstract: BACKGROUND Ulcerative colitis (UC), an idiopathic, chronic inflammatory disorder of the colonic mucosa, is commonly treated with antitumor necrosis factor α (anti-TNF-α) agents. However, only approximately two-thirds have an initial response to these therapies. METHODS… read more here.
Keywords: anti tnf; response; logor score; tnf therapy ... See more keywords